冠心病降脂治疗新进展——Evinacumab

New development of lipid-lowering therapy of coronary heart disease: Evinacumab

纯合子家族性高胆固醇血症(HoFH)是一种罕见的由于基因缺失导致的脂质代谢紊乱的疾病,传统的他汀类药物或者枯草溶菌素转化酶9(PCSK9)抑制剂降脂治疗效果不佳。Evinacumab针对这类患者,可以有效降低低密度脂蛋白胆固醇(LDL-C)水平。本文概述了Evinacumab的最新进展,汇总了Evinacumab的II期和III期临床试验研究结果,Evinacumab的副作用和其正在进行的相关临床试验,并介绍了Evinacumab的临床应用现状。

Homozygous familial hypercholesterolemia is a rare genetic disorder of lipid metabolism,traditional lipid-lowering therapies such as statins and proprotein convertase subtilisin-kexin type 9(PCSK9)inhibitors have little efficacy in these patients.Evinacumab can reduce the levels of LDL-C effectively.In this review,we summarize the latest advances in Evinacumab,and review the phase 2 and phase 3 clinical trials results,adverse events,and the clinical trials results in progress of Evinacumab.Finally,we discuss the current status of Evinacumab in the clinical works.